Adults with Active Psoriatic Arthritis and Obesity
NO LONGER ACCEPTING APPLICATIONS
Published on:
October 17, 2024
Sign-up Expiration:
Updated:
Locations:
Dr. Rakesh Patel
Salisbury, NC
The study aims to evaluate the efficacy and safety of Ixekizumab and Tirzepatide at the maximum tolerated dose in adult participants with active psoriatic arthritis and obesity. The primary endpoint is simultaneously achieving ACR50 and at least 10% weight reduction.
ENDED